Evaluation of the pertussis-specific humoral and cellular immunity after vaccination with REPEVAX® or COVAXiS® or COVAXiS® + IPV Merieux® among three groups: Group A: Adolescents 10-14 years of age who participated in study 371-03/01 and therefore have already received five doses of acellular pertussis vaccine and that simultaneously participate in the TRI05 study where they receive either REPEVAX® or COVAXiS® + IPV Merieux® depending on their randomization group. Group B: Adolescents 10-14 years of age that previously received four doses of acellular pertussis vaccine. Group C: Adolescents 10-14 years of age who previously received four doses of whole-cell pertussis vaccine and have not yet received acellular pertussis vaccine and that simultaneously participate in the TRI05 study where they receive either REPEVAX® or COVAXiS® + IPV Merieux® depending on their randomization group.